<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Low molecular weight (LMW) <z:chebi fb="5" ids="28304">heparin</z:chebi>, with or without aspirin (<z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi> [<z:chebi fb="37" ids="15365">ASA</z:chebi>]), is used to prevent complications in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> in pregnancy </plain></SENT>
<SENT sid="1" pm="."><plain>Our objective was to elucidate the actions of low-dose LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="37" ids="15365">ASA</z:chebi> on basal and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-induced modulation of trophoblast function </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The human first-trimester trophoblast cell line (HTR-8) was treated with or without <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> in the presence of no medication, low-dose LMW <z:chebi fb="5" ids="28304">heparin</z:chebi>, low-dose <z:chebi fb="37" ids="15365">ASA</z:chebi>, or combination therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Interleukin (IL)-6, IL-8, IL-1β, growth-regulated oncogene-α, vascular endothelial growth factor (VEGF), placental growth factor, soluble FMS-like tyrosine kinase-1, and soluble endoglin were measured in the supernatant </plain></SENT>
<SENT sid="4" pm="."><plain>Cell migration was performed using a two-chamber assay </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> improved basal trophoblast migration and induced potent increases in growth-regulated oncogene-α and soluble FMS-like tyrosine kinase-1 </plain></SENT>
<SENT sid="6" pm="."><plain>Aspirin did not affect basal function </plain></SENT>
<SENT sid="7" pm="."><plain>Combined therapy promoted migration but did not reverse the LMW <z:chebi fb="5" ids="28304">heparin</z:chebi>-induced soluble FMS-like tyrosine kinase-1 effect </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> increased IL-8, IL-1β, growth-regulated oncogene-alpha, VEGF, placental growth factor, and soluble endoglin secretion, while decreasing cell migration and IL-6 and soluble FMS-like tyrosine kinase-1 secretion </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-induced cytokine changes were best reversed with LMW <z:chebi fb="5" ids="28304">heparin</z:chebi>, with partial reversal of IL-8 and IL-1β upregulation </plain></SENT>
<SENT sid="10" pm="."><plain>The <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-induced angiogenic changes were worsened by LMW <z:chebi fb="5" ids="28304">heparin</z:chebi>, with increased soluble FMS-like tyrosine kinase-1 secretion </plain></SENT>
<SENT sid="11" pm="."><plain>The therapies did not reverse <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-induced decrease in migration </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: In the absence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> induces potentially detrimental proinflammatory and antiangiogenic profile in the trophoblast </plain></SENT>
<SENT sid="13" pm="."><plain>In the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, single-agent LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> may be the optimal therapy to counter trophoblast <z:mp ids='MP_0001845'>inflammation</z:mp>, but also induces an antiangiogenic response </plain></SENT>
<SENT sid="14" pm="."><plain>These findings may explain the inability of current therapies to consistently prevent adverse outcomes </plain></SENT>
</text></document>